clinical trial · NCT06129864
A Global Study of Volrustomig (MEDI5752) for Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma Following Definitive Concurrent Chemoradiotherapy
AstraZeneca·phase3·recruiting·n = 1,145
Locally Advanced Head and Neck Squamous Cell Carcinomavolrustomig
brief summary
The main purpose of this study is to assess the efficacy and safety of volrustomig compared to observation in participants with unresected locally advanced head and neck squamous cell carcinoma (LA-HNSCC) who have not progressed after receiving definitive concurrent chemoradiotherapy (cCRT).
started
Dec 14, 2023
primary completion
Apr 18, 2028
completion
Sep 12, 2030
last updated
Mar 16, 2026
official title
A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig (MEDI5752) as Sequential Therapy Versus Observation in Participants With Unresected Locally Advanced Head and Neck Squamous Cell Carcinoma, Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy (eVOLVE-HNSCC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol